BioIntelliSense announced today that it acquired AlertWatch, an FDA-cleared patient monitoring platform.
AlertWatch offers integration, data analysis and a patented display of contextual patient data to help in clinical decision-making.
BioIntelliSense in August partnered with Medtronic on the distribution of patient monitoring technology. Through this partnership, it intends to distribute AlertWatch to hospitals throughout the U.S. AlertWatch is now a new offering in the Medtronic HealthCast portfolio.
“The addition of AlertWatch offers healthcare providers comprehensive continuous monitoring solutions, and an accelerated path from adoption to full scale utilization,” said Dr. James Mault, founder and CEO of BioIntelliSense. “The patented AlertWatch multi-parameter interface displays and analyzes data from inpatient vitals, the electronic medical record (EMR), laboratory systems and BioIntelliSense medical-grade wearables, to provide clinical intelligen…